

BIOTRANSPLANT INC  
Form 8-K  
April 29, 2003

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **April 24, 2003**

## BioTransplant Incorporated

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-28324**  
(Commission File Number)

**04-3119555**  
(IRS Employer  
Identification No.)

**200 Boston Avenue**  
**Medford, MA**  
(Address of principal  
executive offices)

**02129**  
(Zip Code)

Registrant's telephone number, including area code: **781-393-8500**

N/A

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

(Former name or former address, if changed since last report)

---

Item 5. Other Events.

On April 24, 2003, BioTransplant Incorporated (the "Company") issued a press release providing an update on the clinical development status of MEDI-507, the Company's monoclonal antibody which has been licensed to MedImmune, Inc.

See the press release attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 25, 2003

BIOTRANSPLANT INCORPORATED

By: /s/ Donald B. Hawthorne  
Donald B. Hawthorne  
President, Chief Executive Officer and  
Chief Financial Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Exhibit</b>
Exhibit 99.1	Press Release dated April 24, 2003